CN100384418C - 异噁唑并吡啶酮类化合物及其在治疗帕金森氏病中的用途 - Google Patents

异噁唑并吡啶酮类化合物及其在治疗帕金森氏病中的用途 Download PDF

Info

Publication number
CN100384418C
CN100384418C CNB028159268A CN02815926A CN100384418C CN 100384418 C CN100384418 C CN 100384418C CN B028159268 A CNB028159268 A CN B028159268A CN 02815926 A CN02815926 A CN 02815926A CN 100384418 C CN100384418 C CN 100384418C
Authority
CN
China
Prior art keywords
phenyl
pyridin
isoxazolo
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028159268A
Other languages
English (en)
Chinese (zh)
Other versions
CN1635889A (zh
Inventor
S·安特曼
B·亨格勒
U·文克罗西克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1635889A publication Critical patent/CN1635889A/zh
Application granted granted Critical
Publication of CN100384418C publication Critical patent/CN100384418C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB028159268A 2001-08-15 2002-08-14 异噁唑并吡啶酮类化合物及其在治疗帕金森氏病中的用途 Expired - Fee Related CN100384418C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0119911.6 2001-08-15
GBGB0119911.6A GB0119911D0 (en) 2001-08-15 2001-08-15 Organic Compounds

Publications (2)

Publication Number Publication Date
CN1635889A CN1635889A (zh) 2005-07-06
CN100384418C true CN100384418C (zh) 2008-04-30

Family

ID=9920454

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028159268A Expired - Fee Related CN100384418C (zh) 2001-08-15 2002-08-14 异噁唑并吡啶酮类化合物及其在治疗帕金森氏病中的用途

Country Status (24)

Country Link
US (1) US7087756B2 (enExample)
EP (1) EP1418912B1 (enExample)
JP (1) JP2005501847A (enExample)
KR (1) KR20040029429A (enExample)
CN (1) CN100384418C (enExample)
AR (1) AR036351A1 (enExample)
AT (1) ATE355059T1 (enExample)
BR (1) BR0211903A (enExample)
CA (1) CA2454762A1 (enExample)
CO (1) CO5560566A2 (enExample)
DE (1) DE60218484T2 (enExample)
EC (1) ECSP044971A (enExample)
ES (1) ES2282467T3 (enExample)
GB (1) GB0119911D0 (enExample)
HU (1) HUP0401325A3 (enExample)
IL (1) IL160018A0 (enExample)
MX (1) MXPA04001419A (enExample)
NO (1) NO20040659D0 (enExample)
PE (1) PE20030356A1 (enExample)
PL (1) PL366848A1 (enExample)
PT (1) PT1418912E (enExample)
RU (1) RU2004107847A (enExample)
WO (1) WO2003015780A2 (enExample)
ZA (1) ZA200400525B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2451057A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
MXPA06013196A (es) * 2004-05-14 2007-02-14 Irm Llc Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar).
JP2009527478A (ja) * 2006-02-16 2009-07-30 ザ マクレーン ホスピタル コーポレーション パーキンソン病の治療のための方法と組成物
AU2007275301A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
FR2933609B1 (fr) * 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
CN102361640B (zh) 2009-01-13 2016-10-19 范安德尔研究所 异噁唑吡啶酮在制备用于缓解或减轻温血哺乳动物关节炎和哮喘的症状的药物中的用途
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
DE102011085038A1 (de) 2011-10-21 2013-04-25 Tesa Se Verfahren zur Kapselung einer elektronischen Anordnung
KR20160060688A (ko) 2013-09-25 2016-05-30 반 안델 리서치 인스티튜트 고도로 강력한 글루코코르티코이드
KR20170033630A (ko) 2015-09-17 2017-03-27 (주)다올 도로용 경계블럭
EP3525870B1 (en) 2016-10-14 2023-05-10 Van Andel Research Institute Highly potent glucocorticoids

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049813A (en) * 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
US4064251A (en) * 1976-06-25 1977-12-20 Sandoz, Inc. Substituted hydroxy pyridones
US4158735A (en) * 1977-01-19 1979-06-19 Sandoz, Inc. Substituted hydroxy pyridones

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7602542L (sv) * 1975-03-14 1976-09-15 Sandoz Ag 3-(alfa-iminobensyl)-4-hydroxi-2(lh)-pyridoner
US4238616A (en) * 1977-01-19 1980-12-09 Sandoz, Inc. 3-(Substituted)phenyl-5-(β-hydroxyphenethyl)-N-(alkyl)-isoxazole-4-carboxamides
US4113727A (en) * 1977-04-26 1978-09-12 Sandoz, Inc. Process for the preparation of substituted isoxazolo[4,5-c]pyridin-4-(5H)-ones
CA2451057A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064251A (en) * 1976-06-25 1977-12-20 Sandoz, Inc. Substituted hydroxy pyridones
US4049813A (en) * 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
US4158735A (en) * 1977-01-19 1979-06-19 Sandoz, Inc. Substituted hydroxy pyridones

Also Published As

Publication number Publication date
ECSP044971A (es) 2004-03-23
RU2004107847A (ru) 2005-05-10
WO2003015780A8 (en) 2004-05-21
WO2003015780A3 (en) 2003-11-13
BR0211903A (pt) 2004-09-21
HUP0401325A3 (en) 2005-09-28
PL366848A1 (en) 2005-02-07
HUP0401325A2 (hu) 2004-10-28
GB0119911D0 (en) 2001-10-10
EP1418912B1 (en) 2007-02-28
DE60218484T2 (de) 2007-11-15
EP1418912A2 (en) 2004-05-19
WO2003015780A2 (en) 2003-02-27
NO20040659L (no) 2004-02-13
DE60218484D1 (de) 2007-04-12
ES2282467T3 (es) 2007-10-16
CO5560566A2 (es) 2005-09-30
ATE355059T1 (de) 2006-03-15
ZA200400525B (en) 2005-04-01
PT1418912E (pt) 2007-05-31
US7087756B2 (en) 2006-08-08
NO20040659D0 (no) 2004-02-13
CA2454762A1 (en) 2003-02-27
CN1635889A (zh) 2005-07-06
MXPA04001419A (es) 2004-05-27
US20040248893A1 (en) 2004-12-09
AR036351A1 (es) 2004-09-01
JP2005501847A (ja) 2005-01-20
PE20030356A1 (es) 2003-05-14
KR20040029429A (ko) 2004-04-06
IL160018A0 (en) 2004-06-20

Similar Documents

Publication Publication Date Title
JP6638036B2 (ja) 有機化合物
JP6486940B2 (ja) アリールエーテルおよびその使用
CA3018185C (en) Allosteric modulators of nicotinic acetylcholine receptors
CN100384418C (zh) 异噁唑并吡啶酮类化合物及其在治疗帕金森氏病中的用途
CN101006065B (zh) 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
CN100475795C (zh) 用作Nurr1激活剂的杂环化合物
CN110582500B (zh) 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途
JP2015178457A (ja) ピラゾロピリジン誘導体、またはその薬理学的に許容される塩
CN101679272B (zh) 作为腺苷a3受体配体的三唑并[1,5-a]喹啉类
TW200400963A (en) R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
CA2677995A1 (en) Acylguanidine derivative
CN112521386B (zh) 具有抗病毒作用的多环吡啶酮化合物及其药物组合和用途
TWI851890B (zh) 抗病毒性1,3-二氧代茚化合物
CN111801333A (zh) 作为正粘病毒复制抑制剂用于治疗流感的10-(二(苯基)甲基)-4-羟基-8,9,9a,10-四氢-7H-吡咯并[1’,2’:4,5]吡嗪并[1,2-b]哒嗪-3,5-二酮衍生物及相关化合物
JP2021503466A (ja) 抗ＨＢＶのテトラヒドロイソキサゾロ［４，３−ｃ］ピリジン類化合物
CA3178647A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
JP2008526818A (ja) Ｐｄｅ１０インヒビターとしての新規のピロロジヒドロイソキノリン
CN114874174B (zh) 具有抗乙肝病毒和冠状病毒作用的苯并二氢吡喃类化合物
CN112189009A (zh) 作为tcr-nck相互作用的抑制剂的色烯衍生物
JP4458745B2 (ja) パピローマウイルス阻害剤
AU2002336977A1 (en) Isoxazolopyridinones and use thereof in the treatment of Parkinson's disease
CN112079829A (zh) 1,2,4-三氮唑并[4,3-a]吡啶类衍生物及其制备方法和用途
NZ785933A (en) Allosteric modulators of nicotinic acetylcholine receptors
HK1105963B (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080430

Termination date: 20110814